SUBSCRIBE: Print / eNewsletter
There's reason to question whether lenalidomide is the cause of secondary cancers in patients who take it as an adjuvant. But new scrutiny may help to clarify how it acts against the primary.
An ethnographic study of palliative care specialists reveals that many of them find dealing with dying patients a gratifying experience. The scant evidence about oncologists on this subject paints a much different picture.
P13K inhibitors, now in the earliest stages of clinical testing, receive hopeful attention as an alternative for patients with aromatase inhibitor resistance. A new study proposes how they should be used, and for whom.
Patients with advanced melanoma now have access to the BRAF inhibitor PLX4032, which has shown survival advantages in a Phase III trial, as long as they have the "right" mutation. The drug's history so far is proving a case study on the challenges of developing personalized cancer treatment.
Lymphedema develops in nearly half of women treated for breast cancer, and the evidence is growing that upper body exercise is a good way to reduce the risk. Studies show that it's crucial to discuss this at the time of diagnosis, and to bring it up periodically afterwards.
Two-year results from the largest randomized trial of IMRT in head and neck cancer confirm that it dramatically reduces the risk of dysphagia and xerostomia. The study was too small to establish a survival advantage, although the results are encouraging.
Human papilloma virus often lurks in cervical tissue, and it can cause cancer there. But the infection is also often benign, particularly among young women. Biomarkers of transformation are proving useful in helping cytologists to decide when a suspicious-looking Pap result is truly a sign of trouble.
The monoclonal antibody ipilimumab provides the first hopeful option ever for patients with metastatic melanoma. It has some peculiar qualities: Bad side effects are a good sign, and progression after treatment isn't necessarily a bad one.
Most of the youngest Americans have viewed IPods and video games as essentials for many years. Yet their use to distract kids with cancer from their pain is still in beta testing.
Removing an oropharyngeal tumor through the open mouth using robotic instruments now has FDA approval, and its safety is well documented. Comparative evidence of its effectiveness is beginning to trickle in.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
